Advertisement

Carcinoid Crisis in the Intensive Care Unit

  • Ozge Keskin
  • Suayib YalcinEmail author
Reference work entry

Abstract

Carcinoid tumors are slow-growing, usually asymptomatic neuroendocrine tumors of enterochromaffin cell origin. Functional neuroendocrine tumors secrete many different mediators such as histamine, 5-hydroxytryptamine (serotonin), and 5-hydroxytryptophan. Carcinoid syndrome is characterized by episodic flushing, diarrhea, wheezing, and right heart valve disease due to these mediators. Carcinoid crisis is a very serious complication of carcinoid syndrome and defined as the severe combination of carcinoid syndrome symptoms. The risk of carcinoid crisis varies between 3.4% and 24%. There are many factors triggering the carcinoid crisis. The most common cause is anesthesia and surgery.

There are no well-defined predicting risk factors for the development of carcinoid crisis. However there are some risk factors such as presence of carcinoid syndrome, elevated 5-HIAA, high tumor burden, metastatic disease, carcinoid heart disease, liver metastases, duration of anesthesia, and advanced patient age.

The aim of the treatment of carcinoid crisis is to block the secretion and effect of mediators released by the tumor and control the symptoms. The cornerstone of this treatment is somatostatin analogs. Other drugs used in the treatment of carcinoid crisis are methylene blue, ketanserin, and H1 and H2 receptor antagonists.

Keywords

Carcinoid syndrome Carcinoid crisis Somatostatin analog Octreotide Lanreotide Ketanserin Histamine Methylene blue 

References

  1. 1.
    Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159(1):358–65.CrossRefGoogle Scholar
  2. 2.
    Davì MV, Bodei L, Francia G, et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Investig. 2006;29(6):563–7.CrossRefGoogle Scholar
  3. 3.
    Fujie S, Zhou W, Fann P, et al. Carcinoid crisis 24 hours after bland embolization: a case report. Biosci Trends. 2010;4(3):143–4.PubMedGoogle Scholar
  4. 4.
    Guo LJ, Tang CW. Somatostatin analogues do not prevent carcinoid crisis. Asian Pac J Cancer Prev. 2014;15(16):6679–83.CrossRefGoogle Scholar
  5. 5.
    Hyman AL, Kadowitz PJ, Lippton HL. Methylene blue selectively inhibits pulmonary vasodilator responses in cats. J Appl Physiol (1985). 1985;66(3):1513–7.CrossRefGoogle Scholar
  6. 6.
    Janssen M, Salm EF, Breburda CS, et al. Carcinoid crisis during transedophageal echocardiography. Intensive Care Med. 2000;26(2):254.CrossRefGoogle Scholar
  7. 7.
    Kılıçkap S, Yalcin S. Introduction to neuroendocrine tumors. In: Yalcin S, editor. Carcinoid syndrome: Springer, Heidelberg; 2015. p. 513–22.Google Scholar
  8. 8.
    Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth. 2001;87(3):447–52.CrossRefGoogle Scholar
  9. 9.
    Koopmans KP, Brouwers AH, De Hooge MN, et al. Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med. 2005;46(7):1240–3.PubMedGoogle Scholar
  10. 10.
    Kromas M, Passi Y, Kuzumi C, et al. Intraoperative carcinoid crisis: revised anaesthesia management. Ind J Anaesth. 2017;61(5):85–6.Google Scholar
  11. 11.
    Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.CrossRefGoogle Scholar
  12. 12.
    Kvols LK, Martin JK, Marsh HM, et al. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med. 1985;313:1229–30.PubMedGoogle Scholar
  13. 13.
    Lyseng-Williamson KA. Telotristat ethyl: a review in carcinoid syndrome diarrhoea. Drugs. 2018;78(9): 941–50.CrossRefGoogle Scholar
  14. 14.
    Magabe PC, Bloom AL. Sudden death from carcinoid crisis during image-guided biopsy of a lung mass. J Vasc Interv Radiol. 2014;25(3):484–7.CrossRefGoogle Scholar
  15. 15.
    Majeed F, Porter TR, Tarantolo S, et al. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. Eur J Echocardiogr. 2007;8(5):386–9.CrossRefGoogle Scholar
  16. 16.
    Massimino K, Harrskog O, Pommier S, et al. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol. 2013;107(8):842–6.CrossRefGoogle Scholar
  17. 17.
    Mehta AC, Rafanan AL, Bulkley R, et al. Coronary spasm and cardiac arrest from carcinoid crisis during laser bronchoscopy. Chest. 1999;115(2):598–600.CrossRefGoogle Scholar
  18. 18.
    Morrisroe K, Sim I-W, Mc Lachlan K, et al. Carcinoid crisis induced by repeated abdominal examination. Intern Med J. 2012;42(3):342–3.CrossRefGoogle Scholar
  19. 19.
    Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784–98.CrossRefGoogle Scholar
  20. 20.
    Raikhelkar JK, Weiss AJ, Maysick L, et al. Adjuvant therapy with methylene blue in the treatment of postoperative vasoplegic syndrome caused by carcinoid crisis after tricuspid valve replacement. J Cardiothorac Vasc Anesth. 2012;26(5):878–9.CrossRefGoogle Scholar
  21. 21.
    Shapiro MB, Endredi J, Ehrhart IC, et al. Methylene blue restores vasodilation to bradykinin after inhibition of nitric oxide production in the isolated dog lung. J Vasc Res. 1996;33(4):340–5.CrossRefGoogle Scholar
  22. 22.
    Seymour N, Sawh SC. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review. Can J Anaesth. 2013;60(5):492–9.CrossRefGoogle Scholar
  23. 23.
    Sinha V, Dyer P, Shuvro RC, et al. Case of carcinoid crisis following a fine-needle biopsy of hepatic metastasis. Eur J Gastroenterol Hepatol. 2009;21(1):101–3.CrossRefGoogle Scholar
  24. 24.
    Soto Herrera M, Restrepo JA, Díaz JH, et al. Reversible right-sided heart failure secondary to carcinoid crisis. Case Rep Crit Care. 2013;2013:487801.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Tapia Rico G, Li M, Pavlakis N, et al. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions. Cancer Treat Rev. 2018;66:1–6.CrossRefGoogle Scholar
  26. 26.
    van Diepen S, Sobey A, Lewanczuk R, et al. A case of acute respiratory distress syndrome responsive to methylene blue during a carcinoid crisis. Can J Anaesth. 2013;60(11):1085–8.CrossRefGoogle Scholar
  27. 27.
    Woltering EA, Wright AE, Stevens MA, et al. Development of effective prophylaxis against intraoperative carcinoid crisis. J Clin Anaesth. 2016;32:189–93.CrossRefGoogle Scholar
  28. 28.
    Yalcin S, Öberg K. Introduction to neuroendocrine tumors. In: Yalcin S, editor. Neuroendocrine tumors: diagnosis and management: Springer, Heidelberg; 2015. p. 1–5.Google Scholar
  29. 29.
    Yazbek-Karam VG, Haswani RW, Mousallem NM, et al. Severe intra-operative carcinoid crisis in a patient having carcinoid heart disease. Acta Anaesthesiol Scand. 2009;53(3):414–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medical OncologySelçuk UniversityKonyaTurkey
  2. 2.Department of medical oncologyHacettepe University Institute of CancerAnkaraTurkey

Personalised recommendations